世界の注射剤送達市場の規模は、売上ベースで2024年に7,545億ドルと推定され、2024年から2029年にかけて8.6%のCAGRで成長し、2029年には1兆1,394億ドルに達すると予測されます。この包括的な調査には、業界動向の徹底的な調査、綿密な価格分析、特許の精査、会議やウェビナーから得られた洞察、主要な利害関係者の特定、および市場の購買ダイナミクスの微妙な理解が含まれます。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.2.1 KEY INCLUSIONS & EXCLUSIONS
1.3 RESEARCH SCOPE
1.3.1 SEGMENTS COVERED
1.3.2 GEOGRAPHIC SCOPE
1.3.3 YEARS CONSIDERED FOR THE STUDY
1.4 CURRENCY USED FOR THE STUDY
1.5 MAJOR MARKET STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA SOURCES
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
2.2 MARKET SIZE ESTIMATION METHODOLOGY
2.3 MARKET SHARE ESTIMATION METHODOLOGY
2.4 MARKET BREAK DOWN AND DATA TRIANGULATION
2.5 RESEARCH ASSUMPTIONS
2.6 RESEARCH LIMITATIONS
2.6.1 SCOPE RELATED LIMITATIONS
2.6.2 METHODOLOGY RELATED LIMITATIONS
2.7 RISK ASSESSMENT
2.8 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
5 MARKET OVERVIEW
5.1 MARKET DYNAMICS
5.1.1 MAJOR DRIVERS
5.1.2 KEY RESTRAINTS
5.1.3 KEY GROWTH OPPORTUNITIES
5.1.4 INDUSTRY-SPECIFIC CHALLENGES
5.2 TARIFF AND REGULATORY LANDSCAPE
5.2.1 TARIFF CODE RELATED TO INJECTABLE DRUG PRODUCTS
5.2.2 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS
5.2.3 REGULATORY TRENDS, BY REGION
5.3 VALUE CHAIN ANALYSIS
5.4 SUPPLY CHAIN ANALYSIS
5.5 ECOSYSTEM ANALYSIS
5.6 TECHNOLOGY ANALYSIS
5.6.1 KEY TECHNOLOGIES
5.6.1.1 AUTO-INJECTORS
5.6.1.2 MICRONEEDLE
5.6.2 COMPLIMENTARY TECHNOLOGIES
5.6.2.1 BIOCOMPATIBLE MATERIALS
5.6.3 ADJACENT TECHNOLOGIES
5.6.3.1 BIOPHARMACEUTICS
5.7 REIMBURSEMENT SCENARIO
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TRADE DATA
5.1 PATENT ANALYSIS
5.10.1 PATENT PUBLICATION TRENDS FOR THE INJECTABLE DRUG DELIVERY MARKET
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
5.11 PORTER’S FIVE FORCE ANALYSIS
5.12 PRICING ANALYSIS
5.12.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
5.12.2 AVERAGE SELLING PRICE TREND, BY REGION
5.13 CASE STUDY ANALYSIS
5.14 KEY CONFERENCES AND EVENTS IN 2024-25
5.15 KEY STAKEHOLDERS & BUYING CRITERIA
5.15.1 KEY STAKEHOLDERS IN THE BUYING PROCESS
5.15.2 BUYING CRITERIA
5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
5.17 CUSTOMER UNMET NEEDS IN INJECTABLE DRUG DELIVERY MARKET
6 INJECTABLE DRUG DELIVERY MARKET, BY TYPE (USD MILLION; 2021—2029) *
6.1 DEVICES
6.1.1 CONVENTIONAL INJECTION DEVICES
6.1.1.1 By Material
6.1.1.1.1 Glass
6.1.1.1.2 Plastic
6.1.1.2 By Product
6.1.1.2.1 Fillable Syringes
6.1.1.2.2 Prefilled syringes
6.1.1.3 By Usability
6.1.1.3.1 Reusable Injection devices
6.1.1.3.1 Disposable Injection devices
6.1.2 SELF-INJECTION DEVICES
6.1.2.1 Needle-free Injectors
6.1.2.1.1 By Product
6.1.2.1.1.1 Fillable needle-free Injectors
6.1.2.1.1.2 Prefilled needle-free injcetors
6.1.2.1.2 By Technology
6.1.2.1.2.1 Jet-based needle-free injectors
6.1.2.1.2.2 Spring-based needle-free injectors
6.1.2.1.2.3 Laser-powered needle free-injectors
6.1.2.1.2.4 Vibration-based needle-free injectors
6.1.2.1.3 By Usability
6.1.2.1.3.1 Reusable needle-free injectors
6.1.2.1.3.2 Disposable needle-free injectors
6.1.2.2 Autoinjectors
6.1.2.1.4 By Product
6.1.2.1.4.1 Fillable autoinjectors
6.1.2.1.4.1 Prefilled autoinjectors
6.1.2.1.4.2 By Technology
6.1.2.1.4.2 Automated autoinjectors
6.1.2.1.4.2 Manual autoinjectors
6.1.2.1.4.3 By Design
6.1.2.1.4.3 Standardized autoinjectors
6.1.2.1.4.3 Customized autoinjectors
6.1.2.1.4.4 By Usability
6.1.2.1.4.4 Reusable autoinjectors
6.1.2.1.4.4 Disposable autoinjectors
6.1.2.3 PEN INJECTORS
6.1.2.3.1 By Product
6.1.2.3.1.1 Single-chambered pen injectors
6.1.2.3.1.2 Dual-chambered pen injectors
6.1.2.3.2 By Design
6.1.2.3.2.1 Standard pen injectors
6.1.2.3.2.2 Customized pen injectors
6.1.2.3.3 By Usability
6.1.2.3.3.1 Reusable pen injectors
6.1..2.3.3.2 Disposable pen injectors
6.1.2.4 WEARABLE INJECTORS
6.1.2.5 OTHER DEVICES
6.2 FORMULATIONS
6.2.1 CONVENTIONAL DRUG DELIVERY FORMULATIONS
6.2.1.1 Solutions
6.2.1.2 Reconstituted/Lyophilized formulations
6.2.1.3 Suspensions
6.2.1.4 Emulsions
6.2.2 NOVEL DRUG DELIVERY FORMULATIONS
6.2.2.1 COLLOIDAL DISPERSIONS
6.2.2.1.1 Niosomes
6.2.2.1.2 Liposomes
6.2.2.1.3 Polymeric/mixed micelles
6.2.2.1.4 Nanoparticles
6.2.2.1.4.1 Solid-lipid nanoparticles
6.2.2.1.4.2 Nanosuspensions
6.2.2.1.4.3 Nanoemulsions
6.2.2.2 MICROPARTICLES
6.2.2.2.1 Microspheres
6.2.2.2.2 Microcapsules
6.2.3 LONG-ACTING INJECTION FORMULATIONS
7 INJECTABLE DRUG DELIVERY MARKET, BY FORMULATION PACKAGING
7.1 INTRODUCTION
7.2 AMP0ULES
7.3 VIALS
7.4 CARTRIDGES
7.5 BOTTLES
8 INJECTABLE DRUG DELIVERY MARKET, BY THERAPEUTIC APPLICATION
8.1 INTRODUCTION
8.2 AUTOIMMUNE DISEASES
8.2.1 Rheumatoid arthritis
8.2.2 Multiple Sclerosis (MS)
8.2.3 Crohn’s Disease
8.2.4 Psoriasis
8.2.5 Other Autoimmune Diseases
8.3 HORMONAL DISORDERS
8.3.1 Diabetes
8.3.2 ANEMIA
8.3.3 REPRODUCTIVE HEALTH DISEASE
8.3.4 ANTITHROMBOTIC/THROMBOLYTIC THERAPY
8.3.5 OSTEOPOROSIS
8.3.6 GROWTH HORMONE DEFICIENCY(GHD)
8.4 ORPHAN DISEASES
8.5 CANCER
8.6 INFECTIOUS DISEASES
8.7 OTHER THERAPEUTIC APPLICATIONS
8.6.1 PAIN MANAGEMENT
8.6.2 ALLERGIES
8.6.3 AESTHETIC TREATMENT
8.6.4 HEPATITIS C
8.6.5 HEMOPHILIA
9 INJECTABLE DRUG DELIVERY MARKET, BY USAGE PATTERN
9.1 INTRODUCTION
9.2 CURATIVE CARE
9.3 IMMUNIZATION
9.4 OTHERS
10 INJECTABLE DRUG DELIVERY MARKET, BY SITE OF ADMINISTRATION
10.1 Introduction
10.2 Skin(Intradermal and subcutaneous)
10.3 Circulatory/Musculoskeletal system (Intravenous, Intracardiac, Intramuscular and Intraperitoneal)
10.4 Organs (Intravitreal and Intra-articular)
10.5 Central Nervous system ( Intracerebral and intrathecal)
11 INJECTABLE DRUG DELIVERY MARKET, BY DISTRIBUTION CHANNEL
11.1 Introduction
11.2 Hospitals
11.3 Retail Pharmacy stores
12 INJECTABLE DRUG DELIVERY MARKET, BY PATIENT CARE SETTING
12.1 Introduction
12.2 Hospitals and Clinics
12.3 Home care settings
12.4 Other facilities of Use
13 INJECTABLE DRUG DELIVERY MARKET, BY REGION (USD MILLION; 2021—2029)*
9.1 NORTH AMERICA
9.1.1 RECESSION IMPACT
9.1.2 US
9.1.3 CANADA
9.2 EUROPE
9.2.1 RECESSION IMPACT
9.2.2 GERMANY
9.2.3 UK
9.2.4 FRANCE
9.2.5 ITALY
9.2.6 SPAIN
9.2.7 REST OF EUROPE
9.3 ASIA-PACIFIC
9.3.1 RECESSION IMPACT
9.3.2 JAPAN
9.3.3 CHINA
9.3.4 INDIA
9.3.5 SOUTH KOREA
9.3.6 AUSTRALIA
9.3.7 REST OF ASIA-PACIFIC
9.4 LATIN AMERICA
9.4.1 RECESSION IMPACT
9.4.2 BRAZIL
9.4.3 MEXICO
9.4.4 REST OF LATIN AMERICA
9.5 MIDDLE EAST AND AFRICA
9.5.1 RECESSION IMPACT
9.4.3 GCC COUNTRIES
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
10.3 REVENUE ANALYSIS OF KEY PLAYERS (2023)
10.4 MARKET SHARE ANALYSIS
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
9.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
10.5.5.1 COMPANY FOOTPRINT
10.5.5.2 REGION FOOTPRINT
10.5.5.3 OFFERING FOOTPRINT
10.5.5.4 CONNECTIVITY FOOTPRINT
10.5.5.5 END-USE APPLICATION FOOTPRINT
10.6 COMPANY EVALUATION MATRIX: STARTUPS/ SMES, 2023
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
10.6.5.1 DETAILED LIST OF KEY STARTUPS/SMES
10.6.5.2 COMPETITIVE BENCHMARKING OF STARTUPS/SMES
10.7 COMPETITIVE SCENARIO AND TRENDS (2021-2023)
10.7.1 PRODUCT LAUNCHES
10.7.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS
10.7.3 MERGERS & ACQUISITIONS
10.7.4 EXPANSIONS
10.8 INVESTMENT AND FUNDING SCENARIO
10.9 INJECTABLE DRUG DELIVERY MARKET, BRAND/PRODUCT COMPARATIVE ANALYSIS
11 COMPANY PROFILES**
(Business Overview, Products Offered, Industry-specific Developments for 2021-2023)***
11.1 KEY COMPANIES
11.1.1 INJECTABLE DRUG DELIVERY FORMULATIONS MANUFACTURERS
11.1.1.1 BECTON ,DICKINSON AND COMPANY
11.1.1.2 PFIZER INC.
11.1.1.3 NOVARTISINTERNATIONALAG
11.1.1.4 SANOFI S.A
11.1.1.5 JOHNSON & JOHNSON
11.1.1.6 MERCK & CO., INC
11.1.1.7 GLAXOSMITHKLINE PLC
11.1.1.8 TEVAPHARMACEUTICALINDUSTRIESLTD.
11.1.1.9 FRESENIUS SE & CO. KGAA
11.1.1.10 ELI LILLY AND COMPANY
11.1.1.11 SUN PHARMACEUTICAL INDUSTRIESLTD
11.1.2 INJECTABLE DRUG DELIVERY DEVICES MANUFACTURERS
11.1.2.1 TERUMO CORPORATION
11.1.113 B. BRAUN MELSUNGEN AG
11.1.114 FRESENIUS KABI AG
11.1.115 SMITHS MEDICAL
11.1.116 YPSOMED HOLDING AG
11.1.117 GERRESHEIMER AG
11.1.118 WESTPHARMACEUTICALSERVICES,INC
11.1.119 SCHOTT PHARMA
11.1.120 ANATARES PHARMA (HALOZYME)
11.1.121 BAXTER INTERNATIONAL INC.
12 APPENDIX
